Mesa Laboratories Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesa Laboratories in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Mesa Laboratories stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLAB, but not buy additional shares or sell existing shares.
View analyst ratings for Mesa Laboratories or view top-rated stocks.

Wall Street analysts have given Mesa Laboratories a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mesa Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Mesa Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Mesa Laboratories.

Mesa Laboratories, Inc. (NASDAQ:MLAB) issued its quarterly earnings results on Monday, May, 31st. The medical instruments supplier reported $0.74 EPS for the quarter, missing the Zacks' consensus estimate of $0.91 by $0.17. The medical instruments supplier earned $37.96 million during the quarter, compared to analyst estimates of $34.92 million. Mesa Laboratories had a trailing twelve-month return on equity of 6.20% and a net margin of 2.92%.
View Mesa Laboratories' earnings history.

Mesa Laboratories' stock was trading at $230.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MLAB stock has increased by 35.1% and is now trading at $312.00.
View which stocks have been most impacted by COVID-19.

Mesa Laboratories announced a quarterly dividend on Tuesday, July 6th. Shareholders of record on Tuesday, August 31st will be paid a dividend of $0.16 per share on Wednesday, September 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date of this dividend is Monday, August 30th.
View Mesa Laboratories' dividend history.

Mesa Laboratories pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.20%. Mesa Laboratories does not yet have a strong track record of dividend growth. The dividend payout ratio of Mesa Laboratories is 12.21%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Mesa Laboratories will have a dividend payout ratio of 13.76% next year. This indicates that Mesa Laboratories will be able to sustain or increase its dividend.
View Mesa Laboratories' dividend history.

2 analysts have issued 12-month price objectives for Mesa Laboratories' stock. Their forecasts range from $260.00 to $287.00. On average, they expect Mesa Laboratories' share price to reach $273.50 in the next year. This suggests that the stock has a possible downside of 12.3%.
View analysts' price targets for Mesa Laboratories or view top-rated stocks among Wall Street analysts.

5 employees have rated Mesa Laboratories CEO Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among Mesa Laboratories' employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Mesa Laboratories include Cognex (CGNX), Coherent (COHR), National Instruments (NATI), Itron (ITRI), Badger Meter (BMI), OSI Systems (OSIS), FARO Technologies (FARO), Vishay Precision Group (VPG) and Daktronics (DAKT).
View all of MLAB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and (BDX).

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Mesa Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.93%), Conestoga Capital Advisors LLC (9.78%), Vanguard Group Inc. (6.07%), Invesco Ltd. (4.97%), Price T Rowe Associates Inc. MD (3.68%) and State Street Corp (3.61%). Company insiders that own Mesa Laboratories stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Robert V Dwyer.
View institutional ownership trends for Mesa Laboratories.

MLAB stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Millennium Management LLC, Kayne Anderson Rudnick Investment Management LLC, Morgan Stanley, Morgan Stanley, Russell Investments Group Ltd., Invesco Ltd., and Conestoga Capital Advisors LLC. Company insiders that have sold Mesa Laboratories company stock in the last year include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, and John Sakys.
View insider buying and selling activity for Mesa Laboratories or view top insider-selling stocks.

MLAB stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Eagle Asset Management Inc., Renaissance Technologies LLC, Northern Trust Corp, State Street Corp, Bridgewater Associates LP, Dimensional Fund Advisors LP, and Geode Capital Management LLC.
View insider buying and selling activity for Mesa Laboratories or or view top insider-buying stocks.

Shares of MLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MLAB stock can currently be purchased for approximately $312.00.

Mesa Laboratories has a market capitalization of $1.62 billion and generates $133.94 million in revenue each year. The medical instruments supplier earns $3.27 million in net income (profit) each year or $5.24 on an earnings per share basis.

Mesa Laboratories employs 506 workers across the globe.

The official website for Mesa Laboratories is www.mesalabs.com.

Mesa Laboratories is headquartered at 12100 W 6TH AVE, LAKEWOOD CO, 80228.

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The medical instruments supplier can be reached via phone at (303) 987-8000 or via email at [email protected].